Pharmaceuticals, Biotechnology & Life Sciences

EU approves Pfizer‑BioNTech’s new mRNA COVID‑19 vaccine—boosting sales, margins and strategic positioning amid variant‑driven demand and competitive pressures.

New Nordisk shares fell as the Phase‑III trial of Ziltivekimab failed to reduce cardiovascular events, highlighting the challenges of anti‑inflammatory heart therapies and the company’s reliance on core GLP‑1 products.

Haleon plc reports a steady 2.4p interim dividend, reaffirms focus on core brands like Advil, Centrum and Sensodyne, and previews its July earnings call.

Takeda Q1 2026: revenue up 5.4% despite net‑profit dip, driven by yen gain and flagship drugs, while operating margin grows and pipeline strength keeps growth prospects strong.

Alnylam’s Q2 2026 results turn a net loss into $164 M profit, powered by a 37 % jump in AMVUTTRA sales, yet a revised revenue outlook and market drop expose risks and opportunities for growth.

United Therapeutics’ July 29 Form 4 shows CEO trades within SEC‑approved windows while the company advances inhaled prostacyclin, CRISPR‑AAV PAP, and a lung‑cancer immunotherapy combo.

AbbVie’s Q2 earnings reveal a pharma pivot: Humira sales dip yet oncology pipeline and Allergan integration drive growth, with macro and biosimilar risks highlighted.

Explore Bayer’s bid to expand Kerendia for non‑diabetic CKD in China, its strategic impact on the fast‑growing CKD market, and the global precision‑medicine shift.

Pfizer’s Litfulo phase‑III wins and new XFG‑variant COVID‑19 vaccine launch boost its dermatology and vaccinology portfolios with strong efficacy and safety.

Investors weigh Novo Nordisk’s €45 share price and GLP‑1 obesity strategy, noting slowing uptake of Wegovy and Zepbound, new combination therapies, and a 2030‑2033 patent cliff that could reshape market dynamics.